Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 12/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | EED | O75530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL935861 | 0.90 | NR1H2 (0.32) | NR1H2 | |
| SCHEMBL12913266 | 0.85 | NR1H2 (0.39) | NR1H2NR1H3NPC1BRD4CREBBP | |
| SCHEMBL12913226 | 0.83 | NR1H2 (0.41) | NR1H2NR1H3NPC1 | |
| SCHEMBL950021 | 0.83 | NR1H2 (0.49) | NR1H2NR1H3BRD4CREBBP | |
| SCHEMBL951156 | 0.82 | KLKB1 (0.34) | NR1H2 | |
| SCHEMBL935475 | 0.81 | NR1H2 (0.38) | NR1H2NR1H3NPC1BRD4CREBBP | |
| SCHEMBL1057502 | 0.81 | RPS6KA3 (0.31) | TTK | |
| SCHEMBL935102 | 0.80 | NR1H2 (0.38) | NR1H2NR1H3NPC1 | |
| SCHEMBL948175 | 0.80 | NR1H2 (0.36) | NR1H2NR1H3BRD4CREBBP | |
| SCHEMBL935103 | 0.80 | NR1H2 (0.34) | NR1H2NR1H3NPC1BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | NR1H2 3426/4885NR1H3 3519/4885NPC1 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.